Instructor, Medicine, UCSF School of Medicine
Hematology
Dr. Adam S. Giermasz, MD
|
|
Give Review
Doctor Adam S. Giermasz, MD is an expert in the field of Hematology. He went to medical school at Medical University of Warsaw. He received awards:"CMS Meaningful Use Stage 1 Certification". Adam Giermasz is a published doctor and has 40 publications published. The lastest was: 'Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?' He accepts all Medicare patients.
Publications
- Helper function of memory CD8+ T Cells: heterologous CD8+ T Cells support the induction of therapeutic cancer immunity.
- Helper roles of NK and CD8+ T Cells in the induction of tumor immunity. Polarized dendritic Cells as cancer vaccines.
- Natural killer-dendritic Cell cross-talk in cancer immunotherapy.
- Helper role of NK Cells during the induction of anticancer responses by dendritic Cells.
- Increased local vascular endothelial growth factor expression Associated with antitumor activity of proteasome inhibitor.
- Apoptosis induced in L1210 leukaemia Cells by an inhibitor of the chymotrypsin-like activity of the proteasome.
- Dendritic Cells mediate NK Cell help for Th1 and CTL responses: two-signal requirement for the induction of NK Cell helper function.
- Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic Cells: tissue-dependent differences offset CD8alpha-related dendritic Cell heterogeneity.
- Augmented antitumour effects of combination therapy With TNP-470 and chemoimmunotherapy in mice.
- A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma With a low apoptotic index.
- Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer Cell lines.
- Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma Cell line.
- Potentiating antitumor effects of a combination therapy With lovastatin and butyrate in the Lewis lung carcinoma model in mice.
- Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
- IL-12 or IL-15, unlike IL-2, does not interact With histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.
- Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice.
- Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 Leukemia in vivo.
- Antitumor activity of tributyrin in murine melanoma model.
- Lovastatin and simvastatin are modulators of the proteasome.
- Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
- Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment With G-CSF.
- Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
- Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice.
- The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production.
- Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 Leukemia in vivo.
- Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
- Re: Macrophage role in the anti-proState cancer response to one class of antiangiogenic agents.
- Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.
- Inhibition of proteasome, apoptosis and sensitization to tumour necrosis factor alpha: do they always go together?
- Effective chemo-immunotherapy of L1210 Leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.
- Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice.
- G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice.
- Augmented antitumor effects of combination therapy With interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
- Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice.
- Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
- Granulocyte-macrophage colony-stimulating factor accelerates growth of Lewis lung carcinoma in mice.
- Augmentation of antitumor efficacy by the combination of actinomycin D With tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice.
- Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice.
- Type-1 polarized dendritic Cells primed for high IL-12 production show enhanced activity as cancer vaccines.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Defects in Pregnancy and Postpartum
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
UCSF -
University of Pittsburgh Medical Center -
Medical University of Warsaw
Hospital
-
University of California, Davis Medical Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1831374644 | |
| NPPES Provider LastName | GIERMASZ | |
| NPPES Provider FirstName | ADAM | |
| NPPES Provider ZIPCode | 941432204 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology | |
| Total Claim Count | 58.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831374644 |
| Last Name Of The Provider | GIERMASZ |
| First Name Of The Provider | ADAM |
| View All |
Similar Doctors
|
|
Dr. Kathleen M. Grant, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori A. Kunkel, MD |
|
|
Dr. Alan B. Glassberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William F. Novotny, MD |
|
|
Dr. William J. Karlon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zuoqin Tang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Trever G. Bivona, MD |
|
|
Dr. Edward N. Cha, MD |
|
|
Dr. Won Kim, MD |
|
|
Dr. David Y. Oh, MD |
|
|
Dr. Ivan J. Silverberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine A. Sanders, MD |
|
|
Chia-Ching J. Wang |